Eloxx Pharmaceuticals, Inc. ELOX NASDAQ · Healthcare · United States
$10.69 +0.38% +$0.04
Summary
No overall score for this company yet.
What speaks for it
- It earns 59 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $56.3M against $11.8M.
What to watch
- It passes only 3 of the 9 points of the Piotroski financial health test.
- For every 100 USD of bills due within a year it has 31 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Is it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $37.67 is 252% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.